TB-500 Dosage: Loading, Maintenance, and Reconstitution Protocols

TB-500 is a synthetic peptide derived from Thymosin Beta-4 (TΒ4), a naturally occurring protein of 43 amino acids (molecular weight approximately 4,963 Da) that is present in nearly all human cells with the exception of red blood cells. Thymosin Beta-4 is the most abundant member of the beta-thymosin family and functions primarily as an actin-sequestering protein, meaning it binds monomeric actin (G-actin) and regulates the assembly and disassembly of the actin cytoskeleton. This activity underpins its role in cell migration, angiogenesis, and tissue repair.

TB-500 itself is most often described as a synthetic fragment corresponding to the biologically active region of Thymosin Beta-4, frequently cited as a 17-amino-acid sequence containing the actin-binding domain. Because it represents the functional core of the parent molecule, researchers study it as a more accessible analog for investigating wound healing, cell migration, and regenerative processes observed in preclinical models. It is important to distinguish between the full recombinant Thymosin Beta-4 used in some clinical research and the TB-500 fragment commonly sold for laboratory use.

Dosage matters for several interrelated reasons. First, peptides exhibit dose-dependent effects in laboratory models, and the relationship between concentration and biological response is rarely linear. Second, TB-500 has a relatively short circulating half-life in its unmodified form, which influences how frequently it is administered in research designs. Third, and most importantly, there are no established human therapeutic dosing guidelines because the compound has not completed the clinical trial process required for approval.

For readers new to this class of molecules, our overview of what peptides are provides useful background on how amino-acid chains differ from full proteins and why their pharmacology is distinct. The detailed monograph on TB-500 covers its mechanism and research history in greater depth than this dosage-focused guide.

This article is for educational purposes only. TB-500 is a research peptide not approved for human use; consult a qualified healthcare professional before considering any peptide.

The terms loading phase and maintenance phase describe a two-stage dosing structure that appears throughout the research-peptide literature and community protocols. The underlying logic borrows from established pharmacology: a loading dose is used to reach a target tissue concentration more quickly, after which a smaller maintenance dose sustains that concentration over time. It is essential to understand that this framework, as applied to TB-500, is derived from preclinical reasoning and anecdotal research reports rather than from validated human pharmacokinetic studies.

During a loading phase, administration frequency is typically higher. The goal in research models is to accumulate the peptide in the relevant tissues and to support the early, most active stage of a repair process. This phase is often described as lasting several weeks. Because TB-500 distributes systemically rather than acting only at an injection site, frequency rather than a single large bolus is the variable most often manipulated.

The maintenance phase follows, characterized by reduced frequency. Once the desired concentration has theoretically been established, less frequent dosing is used to sustain it while reducing the total amount of peptide administered. Some research protocols use maintenance dosing for an extended period, while others taper off entirely after a defined cycle.

The table below summarizes the conceptual difference between the two phases as commonly described in the literature:

Researchers studying combination approaches sometimes pair TB-500 with other regenerative peptides; our guide to peptide stacking discusses the rationale and the gaps in evidence for such combinations.

It cannot be stated strongly enough that there is no officially sanctioned human dose for TB-500. The figures discussed here reflect ranges that recur in research reports, vendor documentation, and community-shared protocols. They are presented for educational context, not as recommendations. The absence of completed human clinical trials means that any specific number carries substantial uncertainty regarding both efficacy and safety.

Within these caveats, a frequently cited per-administration amount falls in the range of approximately 2 to 2.5 mg. Weekly totals are then constructed around this unit. During a loading phase, a common pattern described in the literature is a weekly total in the region of 4 to 10 mg, distributed across two or more administrations. During maintenance, the weekly total is typically reduced to around 2 to 6 mg, often delivered in a single weekly dose.

The following table illustrates a representative two-phase structure as described in community and vendor protocols. These numbers are illustrative only:

Several considerations temper these figures. Dose-response data for TB-500 in humans simply do not exist, so the assumption that more peptide produces proportionally greater benefit is unsupported. In animal studies of Thymosin Beta-4, effects have been observed across a range of doses, and the optimal amount appears to depend heavily on the model and endpoint being measured. Larger doses also increase cost and theoretical risk without a corresponding evidence base for added benefit.

For comparison, individuals interested in tissue-repair peptides often also research BPC-157, which has its own distinct dosing literature and a much larger body of preclinical publications. The two are frequently discussed together, but their pharmacology and recommended handling differ.

TB-500 is supplied as a lyophilized (freeze-dried) powder in a sealed vial, typically labeled by total milligram content, for example 5 mg or 10 mg. Before any research use, the powder must be reconstituted into a liquid using bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative). Bacteriostatic water is preferred over plain sterile water for multi-dose vials because the preservative inhibits microbial growth over the days or weeks a reconstituted vial may be stored.

The volume of bacteriostatic water added determines the concentration of the final solution, which in turn determines how many units to draw on an insulin syringe. The core relationship is simple: concentration (mg/mL) = total peptide (mg) ÷ water added (mL). Choosing a convenient concentration makes subsequent measurement easier and reduces the chance of error.

The table below shows how reconstituting a 5 mg vial with different water volumes changes the per-unit dose on a standard U-100 insulin syringe (where 100 units = 1 mL):

To reconstitute properly, the bacteriostatic water should be injected slowly down the inside wall of the vial rather than directly onto the powder, allowing the liquid to dissolve the peptide gently. The vial should then be swirled, not shaken vigorously, because excessive agitation can damage the fragile peptide structure. The solution should become clear; a cloudy or particulate solution suggests a problem and should not be used.

Once reconstituted, TB-500 must be refrigerated (typically 2-8°C) and protected from light. Reconstituted peptide is generally considered stable for a limited number of weeks under refrigeration, whereas the lyophilized powder can be stored frozen for much longer. Always follow the stability guidance provided with the specific product, and discard any solution that changes appearance.

For a comprehensive guide with an integrated calculator and step-by-step protocol, see our Reconstitution App, which also includes a peptide tracking tool.

In research settings, TB-500 is most commonly administered by subcutaneous injection, meaning into the fatty tissue just beneath the skin, using a small-gauge insulin syringe. Subcutaneous delivery is favored for its simplicity and because TB-500 is thought to distribute systemically regardless of the precise injection site. Intramuscular injection is also described in some protocols, particularly where a localized area is the focus of investigation, though the systemic distribution of the peptide means site selection is less critical than with locally acting compounds.

Common subcutaneous sites include the abdomen (avoiding the area immediately around the navel), the upper thigh, and the flank. Rotating injection sites helps minimize local irritation and tissue reactions. Standard aseptic technique is essential: cleaning the vial stopper and the injection site with an alcohol swab, using a new sterile needle for each injection, and never sharing equipment.

A practical sequence for drawing a dose involves wiping the vial top, drawing back the plunger to the desired unit mark to fill the syringe with air, injecting that air into the vial to equalize pressure, then inverting the vial and drawing the solution to the calculated unit mark. Any air bubbles should be tapped to the top and expelled before injecting, since bubbles displace liquid and reduce the actual delivered dose.

Because the calculation linking milligrams to syringe units depends entirely on the reconstitution concentration, it is worth double-checking the math before each injection, especially when switching to a newly reconstituted vial at a different concentration. A simple arithmetic error here is one of the most common sources of accidental under- or over-dosing.

The descriptions above summarize techniques reported in the research literature for educational purposes. They are not medical instructions. Any parenteral administration carries risks of infection, bleeding, and adverse reaction, and should only be considered under appropriate professional and legal authorization.

Frequency is arguably the most distinctive variable in TB-500 protocols, and it is closely tied to the loading-versus-maintenance distinction discussed earlier. During the loading phase, multiple administrations per week are typical, with two to three injections weekly being a frequently described pattern. The reasoning is that more frequent dosing supports building and sustaining tissue concentrations during the period considered most active for repair processes in research models.

During the maintenance phase, frequency commonly drops to once weekly. This reduction reflects the idea that maintaining an established concentration requires less input than reaching it initially. Some protocols continue maintenance dosing for a defined number of weeks, while others discontinue entirely after the loading phase, treating the cycle as time-limited rather than indefinite.

Regarding time of day, there is no robust evidence indicating that morning versus evening administration meaningfully changes outcomes for TB-500. Unlike growth-hormone-releasing peptides such as CJC-1295, whose timing relative to sleep and meals is considered relevant to their mechanism, TB-500's proposed actions are not tied to circadian hormone pulses. Consistency of scheduling is generally emphasized more than the specific hour.

Cycle length is another consideration. Many community protocols describe total cycles in the range of 4 to 12 weeks, encompassing both phases, after which a break is taken. The absence of long-term human safety data is the central reason that indefinite, continuous use is generally cautioned against in the literature. There is simply no clinical dataset establishing what prolonged TB-500 exposure does in humans over months or years.

Ultimately, every statement about frequency and timing here describes patterns reported by researchers and vendors, not validated dosing schedules. The honest summary is that optimal frequency for any human endpoint remains unknown.

Even within the research-protocol framework, several variables are commonly cited as influencing how TB-500 is dosed. Understanding them clarifies why a single universal number does not exist. The first is body weight. As with many peptides and small-molecule agents, larger individuals are sometimes described as using proportionally higher amounts, though there is no validated milligram-per-kilogram conversion for TB-500 in humans.

A second factor is the research objective. Protocols framed around acute investigation of a specific tissue tend to emphasize a more intensive loading phase, whereas those framed around sustained, lower-level study favor the maintenance pattern. The endpoint being measured shapes both dose and duration in the underlying animal literature.

A third factor is product quality and concentration accuracy. Research peptides vary considerably in purity, and the actual peptide content of a vial may differ from its label if sourced from an unreliable supplier. This directly affects the real delivered dose regardless of careful syringe math. Third-party certificates of analysis are the only objective way to assess what a vial actually contains.

A fourth consideration is individual response and tolerability. Because peptides interact with complex biological systems, responses differ between individuals. Reported considerations include local injection-site reactions and general tolerability, which may lead researchers to adjust frequency. The fragment nature of TB-500 and its short native half-life also influence how its effects are timed and sustained, which is why frequency is manipulated more than single-dose size.

Finally, concurrent compounds matter. When TB-500 is studied alongside other peptides, the combined protocol may be structured differently than for TB-500 alone. The interactions, additive effects, or redundancies of such combinations are poorly characterized in humans, which is an additional reason for caution. Readers can review general principles in our peptide stacking guide.

Safety must frame any discussion of TB-500 dosage. The most important fact is regulatory: TB-500 is not approved by the FDA, the EMA, or any comparable agency for human use. It is classified and sold strictly as a research compound, generally labeled "for research use only." There is no approved indication, no approved dose, and no manufacturer accountable for human safety the way there would be for a licensed medicine.

The evidence base is also limited. While Thymosin Beta-4 has been studied in preclinical models of wound healing, cardiac repair, and corneal injury, and has been the subject of some early-stage clinical research in its full recombinant form, the synthetic TB-500 fragment marketed for research has no completed Phase III human trials establishing efficacy or long-term safety. Most supportive data come from animal studies, which do not reliably translate to human outcomes.

From a sports and competition standpoint, TB-500 is prohibited. The World Anti-Doping Agency (WADA) lists Thymosin Beta-4 and related peptides under the S2 category (peptide hormones, growth factors, and related substances), and they are banned at all times, both in and out of competition. Athletes subject to anti-doping rules face serious consequences for use, regardless of dose.

Reported adverse considerations for peptides in this class include local injection-site reactions such as redness, swelling, or discomfort, transient fatigue or head-rush sensations described anecdotally, and the general infection and injury risks inherent to any injection. Because there is no systematic human safety surveillance, the full adverse-event profile is genuinely unknown, and the absence of reported severe events should not be mistaken for established safety.

Legal status varies by jurisdiction. In many countries, possession for personal use occupies a gray area, while sale for human consumption is restricted. Anyone considering this compound should verify the rules that apply to them. For a fuller statement of the limitations that apply to all content of this type, see our medical disclaimer.

This article is for educational purposes only and does not constitute medical advice. TB-500 is a research peptide not approved for human use. Consult a qualified healthcare professional before considering any peptide, and comply with all applicable laws and anti-doping regulations.